InnoCan Pharma (TSE:INNO)
:INNO
Top Page
InnoCan Pharma
(INNO)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$8.50
▲(13.33% Upside)
Action:ReiteratedDate:01/30/26
The score is weighed down primarily by weak financial performance (ongoing losses and deteriorating cash flow despite strong gross margins and low leverage). Technicals also remain soft with negative MACD and price below key longer-term moving averages. Valuation is only mildly supportive because the negative P/E reflects lack of profitability and no dividend data is available.
Positive Factors
High Gross Margin
An 88.45% gross margin is a durable structural advantage: it indicates strong unit economics or premium product pricing that can absorb SG&A and R&D without immediate margin collapse, supporting sustained investment in development and commercialization over months.
Negative Factors
Negative Profitability
Sustained negative profitability and negative operating margins indicate the business is not yet self-sustaining; this limits retained earnings for reinvestment and requires either rapid operating improvement or external capital to fund growth and translate gross-margin strength into net profits.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
An 88.45% gross margin is a durable structural advantage: it indicates strong unit economics or premium product pricing that can absorb SG&A and R&D without immediate margin collapse, supporting sustained investment in development and commercialization over months.
Read all positive factors
InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$29.65M
Dividend YieldN/A
Average Volume (3M)920.00
Price to Earnings (P/E)―
Beta (1Y)-0.37
Revenue Growth-3.94%
EPS Growth-17.62%
CountryCA
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.60
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)7.71
Price to Sales (P/S)1.35
P/FCF Ratio-25.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InnoCan Pharma Business Overview & Revenue Model
Company Description
InnoCan Pharma (INNO) is a biotechnology company focused on developing innovative therapeutic solutions leveraging cannabinoid-based technologies. The company operates primarily in the pharmaceutical and wellness sectors, with a core emphasis on c...
How the Company Makes Money
InnoCan Pharma generates revenue through several key streams, primarily by developing and commercializing cannabinoid-based pharmaceutical products. The company monetizes its research and development efforts by partnering with other pharmaceutical...
InnoCan Pharma Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.02M | 29.44M | 13.66M | 2.56M | 196.00K | 8.00K |
| Gross Profit | 23.91M | 26.19M | 11.98M | 2.11M | 121.00K | 3.00K |
| EBITDA | -1.25M | 961.00K | -3.77M | -3.85M | -10.04M | -9.90M |
| Net Income | -3.23M | -1.83M | -4.70M | -3.89M | -10.06M | -15.18M |
Balance Sheet | ||||||
| Total Assets | 11.12M | 9.26M | 6.94M | 6.98M | 12.57M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 10.22M | 5.01M | 3.88M | 4.95M | 11.05M | 2.34M |
| Total Debt | 1.52M | 10.00K | 33.00K | 34.00K | 1.00K | 38.00K |
| Total Liabilities | 4.49M | 2.24M | 2.55M | 751.00K | 3.56M | 7.94M |
| Stockholders Equity | 3.85M | 5.17M | 4.10M | 6.39M | 9.05M | -3.61M |
Cash Flow | ||||||
| Free Cash Flow | 558.00K | -1.59M | -3.95M | -6.09M | -6.67M | -3.69M |
| Operating Cash Flow | 572.00K | -1.58M | -3.90M | -6.07M | -6.63M | -3.69M |
| Investing Cash Flow | 53.47K | 54.00K | -84.00K | -31.00K | -48.00K | 0.00 |
| Financing Cash Flow | 1.53M | 2.70M | 2.92M | 125.00K | 15.30M | 4.02M |
InnoCan Pharma Technical Analysis
Negative
7.50
Price Trends
7.20
Negative
9.62
Negative
11.92
Negative
Market Momentum
-0.21
Negative
45.53
Neutral
69.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 7.5 is above the 20-day moving average (MA) of 6.51, above the 50-day MA of 7.20, and below the 200-day MA of 11.92, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 45.53 is Neutral, neither overbought nor oversold. The STOCH value of 69.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.
InnoCan Pharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | C$57.41M | -2.84 | -19.76% | ― | 26.91% | 81.01% | |
46 Neutral | C$29.65M | -6.72 | -71.80% | ― | -3.94% | -17.62% | |
46 Neutral | C$20.54M | -5.29 | -256.01% | ― | ― | ― | |
46 Neutral | C$19.48M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$29.45M | -3.68 | -19.10% | ― | 18.06% | 34.58% |
* Consumer Defensive Sector Average
TSE:INNO
InnoCan Pharma
6.59
-6.41
-49.31%
TSE:ATLE
Willow Biosciences Inc
0.16
0.09
120.27%
TSE:QNTM
Quantum Biopharma
6.00
-3.90
-39.39%
TSE:LABS
MediPharm Labs
0.07
-0.03
-30.00%
TSE:VM
Voyageur Pharmaceuticals
0.12
-0.06
-36.11%
TSE:AVCN
Avicanna
0.16
-0.16
-50.00%
InnoCan Pharma Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Innocan Pharma Targets NYSE American Listing With Concurrent Offering
Positive
Jan 27, 2026
Innocan Pharma Corporation plans to list its common shares on the NYSE American around January 30, 2026, subject to final exchange approval, while simultaneously conducting a concurrent securities offering that will be detailed in future regulator...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Innocan Pharma Targets NYSE American Listing with Concurrent Securities Offering
Positive
Jan 2, 2026
Innocan Pharma Corporation plans to list its common shares on the NYSE American around January 7, 2026, pending final approval of its listing application and continued compliance with exchange requirements. In conjunction with the anticipated U.S....
Business Operations and StrategyProduct-Related Announcements
Innocan Pharma Unveils Promising Advances in CBD Drug Delivery Platform
Positive
Dec 17, 2025
Innocan Pharma announced promising preliminary findings regarding its liposomal cannabidiol (LPT-CBD) technology. Results from tests conducted on Göttingen minipigs demonstrated sustained CBD release in plasma for 28 days after a single subcu...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Innocan Pharma Files Amended Registration for U.S. Public Offering
Neutral
Dec 10, 2025
Innocan Pharma has announced the public filing of an amended registration statement for a proposed public offering in the United States. The offering will consist of units comprising common shares and warrants, with plans to list these on NYSE Ame...
Business Operations and StrategyFinancial Disclosures
Innocan Pharma Reports Q3 2025 Results and Advances Drug Delivery Platform
Neutral
Nov 27, 2025
Innocan Pharma reported its Q3 2025 financial results, showing revenues of $21.6 million, a 10% decrease compared to the previous year. Despite the revenue decline, the company maintained a high gross margin of 90.2% and a stable operating loss. T...
Business Operations and StrategyProduct-Related Announcements
Innocan Pharma’s LPT-CBD Shows Promising Results in Pain Relief Study
Positive
Nov 24, 2025
Innocan Pharma has published promising results from a study on its Synthetic Liposomal Cannabidiol (LPT-CBD) injections, which were administered to goats suffering from chronic pain. The study demonstrated sustained pain relief, improved mobility,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.